Kansas HB2526 restricts health insurance plans from requiring step therapy for FDA-approved cancer drugs.
Kansas HB2526 establishes restrictions on the use of step therapy protocols by health insurance plans for prescription medications. Specifically, it prohibits plans that cover advanced, metastatic cancer and related conditions from requiring patients to fail with another drug before covering an FDA-approved medication. This applies only to drugs consistent with best practices, supported by evidence-based literature, and approved by the FDA.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
Analyze for Free
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.